Patents by Inventor Philipp Weyermann
Philipp Weyermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8524899Abstract: Methods and compositions are provided for forming complexes between dsDNA and novel oligomers comprising fused six-membered rings. By appropriate choice of target sequences and oligomers, complexes comprising oligomer-DNA are obtained with high association constants. The formation of complexes can be used for identification of specific dsDNA sequences, for inhibiting gene transcription, and as a therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific genes.Type: GrantFiled: March 4, 2004Date of Patent: September 3, 2013Assignee: California Institute of TechnologyInventors: Peter B. Dervan, Christoph A. Briehn, Dorte Renneberg, Philipp Weyermann, Raymond Doss, Michael Marques
-
Patent number: 8236818Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.Type: GrantFiled: March 28, 2008Date of Patent: August 7, 2012Assignee: Santhera Pharmaceuticals (Schweiz) AGInventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
-
Publication number: 20110086836Abstract: The present invention relates to substituted phenylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.Type: ApplicationFiled: April 5, 2007Publication date: April 14, 2011Applicant: Santhera Pharmaceuticals (Schweiz) AGInventors: Michael Soeberdt, Holger Deppe, Philipp Weyermann, Stephan Bulat, Andreas Von Sprecher, Achim Feurer, Cyrille Lescop, Marco Hennebohle, Sonja Nordhoff
-
Publication number: 20100324036Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression.Type: ApplicationFiled: December 18, 2008Publication date: December 23, 2010Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Michael Soeberdt, Philipp Weyermann, Herve Siendt, Sonja Nordhoff, Achim Feurer, Miroslav Terinek
-
Publication number: 20100249093Abstract: The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.Type: ApplicationFiled: July 18, 2008Publication date: September 30, 2010Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Marco Henneböhle, Holger Herzner, Michael Soeberdt, Philipp Weyermann, Sonja Nordhoff, Achim Feurer, Holger Deppe, Hervé Siendt, Miroslav Terinek, Christian Rummey
-
Publication number: 20100093697Abstract: The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.Type: ApplicationFiled: March 28, 2008Publication date: April 15, 2010Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Günther Metz, Holger Deppe, Ulrich Abel, Achim Feurer, Inge Ott, Sonja Nordhoff, Michael Soeberdt, Barbara Hoffmann-Enger, Philipp Weyermann, Hervé Siendt, Christian Rummey, Miroslav Terinek, Marco Henneböhle, Holger Herzner, Cesare Mondadori
-
Publication number: 20080058324Abstract: The present invention relates to novel a-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all condition where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.Type: ApplicationFiled: August 22, 2005Publication date: March 6, 2008Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Philipp Weyermann, Andreas Von Sprecher, Marco Hennebohle, Holger Herzner, Cyrille Lescop, Herve Siendt
-
Publication number: 20070293486Abstract: The present invention relates to novel ?-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all condition where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.Type: ApplicationFiled: August 22, 2005Publication date: December 20, 2007Applicant: SANTHERA PHARMACEUTICALS (SCHWEIZ) AGInventors: Philipp Weyermann, Andreas Von Sprecher, Marco Hennebohle, Holger Herzner, Cyrille Lescop, Herve Siendt
-
Publication number: 20070155783Abstract: The present invention relates to novel substituted cyclohexyl and piperidinyl derivatives as melanocortin-4. receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.Type: ApplicationFiled: March 19, 2004Publication date: July 5, 2007Inventors: Michael Soeberdt, Philipp Weyermann, Andreas Sprecher
-
Publication number: 20070037823Abstract: The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders, where the regulation of the MC-4R is involved, can be treated with the compounds of the invention.Type: ApplicationFiled: March 19, 2004Publication date: February 15, 2007Inventors: Michael Soeberdt, Philipp Weyermann, Andreas Von Sprecher, Marco Hennebohle
-
Publication number: 20060258598Abstract: The present invention relates to novel ?-keto carbonyl calpain inhibitors for the treatment of neurodegenerative diseases and neuromuscular diseases including Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and other muscular dystrophies. Disuse atrophy and general muscle wasting can also be treated. Diseases of the eye, in particular cataract, can be treated as well. Generally all conditions where elevated levels of calpains are involved can be treated. The compounds of the invention may also inhibit other thiol proteases such as cathepsin B, cathepsin H, cathepsin L, papain or the like. Multicatalytic Protease (MCP) also known as proteasome may also be inhibited and the compounds can therefore be used to treat cell proliferative diseases such as cancer, psoriasis, and restenosis.Type: ApplicationFiled: March 3, 2004Publication date: November 16, 2006Inventors: Holger Herzner, Philipp Weyermann, Andreas Sprecher, Marco Henneböhle, Cyrille Lescop, Hervé Siendt
-
Publication number: 20060241123Abstract: The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes, and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.Type: ApplicationFiled: March 19, 2004Publication date: October 26, 2006Inventors: Michael Soeberdt, Philipp Weyermann, Andreas Sprecher
-
Publication number: 20050026174Abstract: Methods and compositions are provided for forming complexes between dsDNA and novel oligomers comprising fused six-membered rings. By appropriate choice of target sequences and oligomers, complexes comprising oligomer-DNA are obtained with high association constants. The formation of complexes can be used for identification of specific dsDNA sequences, for inhibiting gene transcription, and as a therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific genes.Type: ApplicationFiled: March 4, 2004Publication date: February 3, 2005Inventors: Peter Dervan, Christoph Briehn, Dorte Renneberg, Philipp Weyermann, Raymond Doss, Michael Marques